

**RELIEVING ORDER**

Date: 01.02.2024

Name : Ms. Aruna Devi  
Designation : Clinical Research Coordinator  
Site : Apollo Research and Innovations, Madurai  
Date of Joining : 21<sup>st</sup> June 2022  
Resignation letter dated : 01<sup>st</sup> Jan 2024  
Relieved On : 01<sup>st</sup> Feb 2024

The resignation submitted by the above employee is accepted.

Zero days' salary in lieu of notice period will be recovered while settling the accounts.

Regards,



Ms. Lakshmi Suresh  
Deputy General Manager - HR & Administration



01 Feb 2024

**TO WHOMSOEVER IT MAY CONCERN**

This is to certify that **Ms. Aruna Devi** had worked in our organization from **21<sup>st</sup> June 2022** to **01<sup>st</sup> Feb 2024** as **Clinical Research Coordinator** and she has been relieved from her duties and responsibilities from **Apollo Research and Innovations – Apollo Speciality Hospitals, Madurai** with effect from **01<sup>st</sup> Feb 2024**.

She was handled the following Clinical Trials as a Research Coordinator:

**Phase-III, Phase-IV & Observational Studies:-**

- **CVD:** “A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORIAN-2 PREVENT)” Under **Dr. C Vivek Bose, Sr. Consultant of Cardiology, Apollo Speciality Hospitals, Madurai.**
- **Stroke:** “A prospective, multi-centered, randomized, parallel group, two-arm, active control, open label, clinical study to evaluate efficacy and safety of Tenecteplase/R-TPR-012 (0.25 mg/kg) compared with Tenectase™ (0.20 mg/kg) in patients with Acute Ischemic stroke”. Under **Dr. S.Meenakshi Sundaram, Sr. Consultant of Neurology, Apollo Speciality Hospitals, Madurai.**
- **Asthma:** “Prospective, multi-center, open-label, single arm, clinical study to evaluate efficacy and safety of OmaliRel® in patients with moderate to severe persistent asthma” Under **Dr. S.Hari Krishnan, Consultant of Pulmonology, Apollo Speciality Hospitals, Madurai.**
- **Prostate Cancer :** “Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate for Injection 3.75mg (Depot) Administered in Subject with Advanced Adenocarcinoma of Prostate: A Randomized, Active Controlled, Comparative, Open Label, Multi-Center, Phase 3 Study” Under **Dr. J.Arun Kumar, Consultant of Urology, Apollo Speciality Hospitals, Madurai.**
- **CVD:** “A Randomized, double-blind, placebo-controlled, multicenter study, to evaluate the effect of inclisiran on preventing major adverse cardiovascular event in high risk primary prevention patients (VICTORIAN 1 PREVENT)” Under **Dr. C Vivek Bose, Sr. Consultant of Cardiology, Apollo Speciality Hospitals, Madurai.**

**She was outstanding in all other initiative at the site, very proactive and a team player.**

During this period, she proved herself and undergone ICH – GCP training.

She will be an asset to any institution, wherever she may get associated with.

With Regards,

*A.P.H.C.*

**Mr. Radha Krishnan S,  
Clinical Trial Administrator (Site In-charge),  
Apollo Research and Innovations,  
Apollo Speciality Hospitals-Madurai.**

